PRIME-ROSE PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials
- Coordinator
- Oslo Universitetssykehus Hf, Norway
- Runs
- 1 July 2023 to 30 June 2028
- Status
- Running
- EU funding
- €6.0m
- Total cost
- €6.0m
- Partners
- 28 organisations in 19 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101104269
What the project is doing
In the project's own words, from its summary on CORDIS.
Millions of people in the EU are negatively affected by cancer, and cancer is one of the leading causes of death and morbidity in Europe (ecis.jrc.europa.eu). The PRIME-ROSE consortium will contribute to the Mission Cancer goal to optimise treatment and support quality of life of more than 3 million people by 2030.The PRIME-ROSE consortium envisions to support Mission Cancer through the following objectives: 1) increase access to optimised and affordable treatment interventions for cancer patients that prolong life and increase quality of life, 2) generate clinical evidence and evaluate effectiveness in Precision Cancer Medicine (PCM)-relevant and synthetically randomised, controlled academic investigator-initiated pragmatic clinical trials, and 3) work together across Europe with relevant experts to implement evidence-based PCM in routine practice and address inequalities in access.
This consortium builds on the truly bottom-up, clinician-initiated family of DRUP-like innovative trials that provide broad access to precision medicine for cancer patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Oslo Universitetssykehus Hf | Oslo | Norway | Coordinator |
| Masarykuv Onkologicky Ustav | Brno | Czechia | Associatedpartner |
| Universitatsklinikum Heidelberg | Heidelberg | Germany | Associatedpartner |
| Region Hovedstaden | Hillerod | Denmark | Participant |
| Sihtasutus Tartu Ulikooli Kliinikum | Tartu | Estonia | Associatedpartner |
| Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio) | Barcelona | Spain | Associatedpartner |
| Hus-Yhtyma | Helsinki | Finland | Participant |
| Centre De Lutte Contre Le Cancer Leon Berard | Lyon | France | Participant |
| Klinicki Bolnicki Centar Split | Split | Croatia | Associatedpartner |
| Orszagos Onkologiai Intezet | Budapest | Hungary | Associatedpartner |
| The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | Dublin | Ireland | Associatedpartner |
| Istituto Europeo Di Oncologia SRL | Milano | Italy | Associatedpartner |
| Nacionalinis Vezio Institutas | Vilnius | Lithuania | Associatedpartner |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Participant |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Associatedpartner |
| Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie -Panstwowy Instytut Badawczy | Warszawa | Poland | Associatedpartner |
| Instituto Portugues De Oncologia Do Porto Francisco Gentil, Epe | Porto | Portugal | Participant |
| Asociatia Centrul Pentru Inovatie in Medicina | Bucharest | Romania | Associatedpartner |
| Centrul De Oncologie Sf Nectarie SRL | Craiova | Romania | Associatedpartner |
| Ihe, Institutet for Halso- Och Sjukvardsekonomi Aktiebolag | Lund | Sweden | Participant |
| Karolinska Institutet | Stockholm | Sweden | Associatedpartner |
| Region Skane | Kristianstad | Sweden | Associatedpartner |
| Region Uppsala | Uppsala | Sweden | Participant |
| Stiftelsen Stockholm School of Economics (sse) Institute for Research | Stockholm | Sweden | Participant |
| Vastra Gotalandsregionen | Vanersborg | Sweden | Associatedpartner |
| Cancer Research UK Lbg | London | United Kingdom | Associatedpartner |
| The University of Manchester | Manchester | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI